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ABSTRACT: The Human Proteome Project (HPP) consortium aims to functionally
characterize the dark proteome. On the basis of the relevance of olfaction in early
neurodegeneration, we have analyzed the dark proteome using data mining in public resources
and omics data sets derived from the human olfactory system. Multiple dark proteins localize
at synaptic terminals and may be involved in amyloidopathies such as Alzheimer’s disease
(AD). We have characterized the dark PITH domain-containing protein 1 (PITHD1) in
olfactory metabolism using bioinformatics, proteomics, in vitro and in vivo studies, and
neuropathology. PITHD1−/− mice exhibit olfactory bulb (OB) proteome changes related to
synaptic transmission, cognition, and memory. OB PITHD1 expression increases with age in
wild-type (WT) mice and decreases in Tg2576 AD mice at late stages. The analysis across 6
neurological disorders reveals that olfactory tract (OT) PITHD1 is specifically upregulated in
human AD. Stimulation of olfactory neuroepithelial (ON) cells with PITHD1 alters the ON
phosphoproteome, modifies the proliferation rate, and induces a pro-inflammatory phenotype.
This workflow applied by the Spanish C-HPP and Human Brain Proteome Project (HBPP) teams across the ON-OB-OT axis can
be adapted as a guidance to decipher functional features of dark proteins. Data are available via ProteomeXchange with identifiers
PXD018784 and PXD021634.
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■ INTRODUCTION
The Human Proteome Project (HPP) is an initiative of the
Human Proteome Organization (HUPO) aiming to character-
ize the human proteome and make this knowledge available to
the broad scientific community.1 During the past years, the
efforts of the international Chromosome-Centric HPP (C-
HPP) consortium have improved the mapping and annotation
of protein components of each human chromosome.2,3 In
parallel, the international Biology and Disease-driven HPP (B/
D-HPP) initiatives have organized the human proteome across
human cell−tissue−organ axis, establishing functional modules
through the integration of technology and biological knowledge
to study human diseases.4 Although the annotation of the
human proteome has made significant progress, caveats exist
regarding the availability of information related to protein
function.5 NeXtProt, the essential reference knowledgebase for
the HPP,6 contains 1813 dark proteins (release 2020−01−17)
corresponding to 559 missing proteins and 1254 proteins with
high confidence at the protein level (PE1) but considered as
functionally uncharacterized (uPE1).1,7 This “dark proteome”
has not revealed any function by database searching, domain
analysis, intrinsic feature analysis, similarity analysis, and
metabolic pathway involvement between others.8 As a new
avenue toward the completion and annotation of the human
proteome, the C-HPP consortium has recently launched the
neXt-CP50 Pilot Project5 for functional characterization of
identified proteins with insufficiently known function. An
experimental workflow based on multiomics analyses, bio-
informatics, immunological detections, and in vitro and in vivo
studies has been recently proposed,5 in order to collaborate with
B/D teams to enhance the annotation of uPE1 proteins in
specific biological scenarios.
In the context of the B/D oriented branch of theHuman Brain
Proteome Project (HBPP),9 the work presented in this paper
originates from members of the Spanish C-HPP initiative and
aims to characterize the dark proteome in human olfactory
system. Taking into account the relevance of the smell sense in
the early diagnosis of neurodegenerative diseases,10 we have
analyzed the expression profile of the dark proteome (neXtProt
release 2020−01−17; query: NXQ_00022) across public
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proteomic and transcriptomic data derived from primary
olfactory areas such as olfactory bulb (OB) and cleft mucus as
well as from specific brain/OB cell lineages. Specifically, we have
focused our attention on the uPE1 PITH (C-terminal
proteasome-interacting domain of thioredoxin-like) domain-
containing protein 1 (PITHD1; C1orf128), previously consid-
ered as a component of the human central proteome.11
Although it has been related to megakaryopoiesis, ovarian
carcinoma, and male fertilization,12−14 functional features
associated with PITHD1 gene are insufficiently known.
Previous reports pointed out that PITHD1 expression is
altered in Alzheimer’s disease (AD) and Parkinson’s disease
(PD) at the level of the OB.15,16 In this study, we have used an
experimental workflow combining neuropathological diagnosis,
coregulation maps, physical and functional interaction data,
transgenic models, intracellular and extracellular proteomics and
immunohistochemical and biochemical approaches to partially
decipher the PITHD1 function in olfactory metabolism.
Together with a cross-disease study to monitor olfactory
PITHD1 expression across multiple neurological phenotypes
with different sensitivity to olfactory dysfunction as well as in a
mouse AD model, in vitro experiments have allowed us to
demonstrate that PITHD1 interferes with the differentiation
state of the human olfactory neuroepithelial (ON) cells,
inducing a pro-inflammatory phenotype in parallel with protein
expression changes associated with the establishment of the
endothelial barrier, neural precursor cell proliferation, JAK-
STAT pathway, and respiratory electron transport.
■ MATERIALS AND METHODS
Materials
The following reagents and materials were used. Anti-PITHD1
(HPA016936), antipolyhistidine-peroxidase (A7058-1VL) and
anti-c-Myc (M4439) antibodies were purchased from Sigma.
Human rPITHD1 was purchased from MyBiosource
(MBS1307571). The protein was expressed in E. coli and N-
terminal His-tagged and C-terminal His-tagged in aseptic
processing and endotoxin removal conditions. Cytokine anti-
body arrays were obtained from Abcam (ab133998) and human
phosphokinase antibody arrays from R&D systems (ARY003B).
Electrophoresis reagents were purchased from Biorad and
trypsin from Promega. TMT kit was purchased from Thermo
(90064).
Human Samples
According to the Spanish Law 14/2007 of Biomedical Research,
informed written consent forms of the Neurological Tissue Bank
of IDIBAPS-Hospital Clinic (Barcelona, Spain) were obtained
for research purposes from relatives of patients included in this
study. The study was conducted in accordance with the
Declaration of Helsinki and all assessments, post-mortem
evaluations, and procedures were previously approved by the
Clinical Ethics Committee of Navarra Health Service (no. 2016/
36). In all cases (Supplementary Table S1) neuropathological
assessments were performed according to standardized neuro-
pathological scoring/grading systems.17−25
Murine Models
Transgenic mice (Tg2576) overexpressing human amyloid
precursor protein (hAPP), carrying the Swedish (K670N/
M671L) familial AD mutation and under control of the prion
promoter,26 were used. Mice were on an inbred C57BL/6/SJL
genetic background. The animals were maintained in positive
pressure-ventilated racks at 25 ± 1◦C with a 12 h light/dark
cycle, fed ad libitum with a standard rodent pellet diet (Global
Diet 2014; Harlan Laboratories, Indianapolis, IN, USA) and had
free access to filtered and UV-irradiated water. All animal care
and experimental procedures were in accordance with European
and Spanish regulations (86/609/CEE; RD1201/2005) and
were approved by the Ethical Committee of the University of
Navarra (no. 018/05). At least three WT and three Tg2576
transgenic mice per stage (2-, 6-, and 18-month-old) were used.
The progressive development of AD signs in our colony has
been previously described.27 PITHD1-deficient (PITHD1−/−)
mice (accession no. CDB1274K) were generated as previously
described.14 All mouse experiments were performed with
consent from the Animal Experimentation Committee of
Tokushima University (T28-58).
Immunohistochemistry
Under xylazine/ketamine anesthesia, animals were perfused
transcardially with saline for 3 min at a 11 mL/min flow, and 4%
paraformaldehyde in phosphate buffered saline (PBS) for 2 min
at a 9 mL/min flow. After perfusion, brains were removed,
postfixed in 4% paraformaldehyde for 1 h at room temperature
and cryoprotected in 30% sucrose solution in PBS overnight at
4◦C. Immunohistochemistry analysis were performed as
previously described.28 OB and hippocampal sections were
incubated overnight with the anti-PITHD1 antibody
(HPA016936) diluted 1:350 in PBS 0.125 M (pH 7.4), 0.5%
Triton X-100, 0.1% BSA and 5% normal goat sera. After washing
(3 × 5 min) in PBS, sections were incubated for 30 min with
biotinylated goat antimouse secondary antibody (DakoCyto-
mation, Glostrup, Denmark) diluted 1:500 in PBS. The sections
were then processed using the avidin−biotin−peroxidase
complex (Vectastain kit, Vector Laboratories, Burlingame, CA,
USA) and reacted with 0.05% 3,3′-diaminobenzidine tetrahy-
drochloride (DAB) and 0.015% H2O2 in 50 mM Tris HCl, pH
7.2. After washing in deionized water, sections were mounted on
gelatinized slides, counterstained with Thionine at 60 °C
(Panreac Quimica, Barcelona, Spain) and coverslipped with
DPX (VWR, Dublin, Ireland).
Cell Culture
ON samples were obtained from control subjects as previously
described.29 The study was reviewed and approved by the local
institutional ethics committee (no. PI_2019/108). After
humidification of the nasal cavity, two separate sterile
interdental brushes were used to obtain samples from the
lower and middle turbinate, and were placed inside Eppendorf
tubes with 250 μL of cold Dulbecco’s Modified Eagle Medium/
Ham F-12 (DMEM/F12) containing 10% FBS, 2% glutamine
and 1% streptomycin−penicillin (supplemented medium)
(GibcoBRL). This procedure was performed separately for
both nostrils. The nasal exfoliates were initially placed in cold
Dulbecco’s Modified Eagle Medium/Ham F-12 (DMEM/F12)
containing 10% FBS, 2% glutamine and 1% streptomycin−
penicillin (GibcoBRL). ON cells suspensions were disaggre-
gated mechanically, and primary cultures were established as
previously described.30 Cells were grown for 3 weeks in
supplemented medium at 37 °C and 5% CO2 before passaging
into flasks (Thermo Scientific, Madrid, Spain). Cells were
dissociated with 0.25% trypsin (GibcoBRL) replated at 4000
cells/cm2 into 75 cm2 flasks and cultured in supplemented
medium. Then, cells were expanded by passage and banked
down in aliquots after harvest, followed by storage in liquid
nitrogen with DMEM/F12, 2% glutamine, 1% streptomycin−
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penicillin, 20% FBS and 10% dimethyl sulfoxide (Sigma-Aldrich,
Madrid, Spain). Frozen aliquots of ON cells at passage 4 were
used. 1 × 106 and 1 × 106 ON cells in triplicates were used for
protein arrays and proteomic analysis, respectively. In all cases,
40uM of human rPITHD1 was directly added to the cell media
during the indicated periods of time. Cell media was collected,
and cells were washed 3 times with 1 × cold PBS, harvested and
immediately frozen in liquid nitrogen. Additionally, cell viability
was determined by crystal violet assay.
Sample Preparation for ON Proteomic Analysis
ON cells and PITHD1-treated ON cells were harvested after 24
h (triplicates). After centrifugation (5 min, 300g), supernatants
were discarded, and pellets were washed with PBS three times to
remove remaining media. Cellular pellets were resuspended in
lysis buffer containing 7M urea, 2 M thiourea, 50 mMDTT and
incubated on ice for 30min, spinning and vortexing each 10min.
After sonication, homogenates were spun down at 20 000g for 1
h. Protein concentration was measured in the supernatants with
the Bradford assay kit (Biorad).
Tandem Mass Tag (TMT)-Based Quantitative Proteomics
Using Trapped Ion Mobility Spectrometry (TIMS-TOF)
A shotgun comparative proteomic analysis of ON cells was
performed combining TMT labeling and TIMS-TOF mass
spectrometry. Briefly, after a precipitation step using the Clean-
up kit (Biorad ref. 1632130), samples were resuspended in 6 M
urea and 100 mM TEAB. Then, equal amounts of ON protein
extract (50 μg) were reduced with 200 mM TCEP during 1 h at
55 °C. Cysteine residues were alkylated with 375 mM IAA at
room temperature for 30 min in darkness. Protein enzymatic
cleavage was carried out with trypsin (Promega; 1:40, w/w) at
37 °C for 16 h. Then, after performing a peptide desalting step
(Thermo Scientific, ref 89852), each tryptic digest was labeled
according to the manufacturer’s instructions with one isobaric
tag: Tag 126, control 1; tag 127, control 2; tag 128, control 3; tag
129 treated 1; tag 130, treated 2; and tag 131, treated 3. After 1 h
of incubation, each set of labeled samples was independently
pooled and evaporated in a vacuum centrifuge.
MS Acquisition and Data Processing
Pooled samples were separated in a HPLC by High pH reverse
phase chromatography using an Agilent Technologies 1200
series, equipped with a Phenomenex Gemini C18 column (150
mm × 2 mm ID, 5um). A chromatographic linear ramp of 30
min (5 to 60% ACN) was used with a flow rate of 500 μL/min,
followed by a washing step of 15 min at 86% ACN.Mobile phase
A was composed by water containing 10 mM Ammonium
formate, pH 10 andmobile phase B was composed by 90% ACN
containing 10 mM Ammonium formate, pH 10. Automatic
sampling collection was performed each minute during ramp
and washing steps. Up to 36 fractions were finally collected (500
μL each). Low-complexity fractions were pooled, whereas high-
complexity samples (based on the UV signal) were analyzed on
their own. A total of 25 different fractions were evaporated using
SpeedVac (Christ corp.), resuspended (in 0.1% FA) and loaded
onto a novel hybrid trapped ion mobility spectrometry−
quadrupole time-of-flight mass spectrometer (TIMS-TOF Pro
with PASEF, Bruker Daltonics) coupled online to a nanoElute
liquid chromatograph (Bruker Daltonics). Samples (approx-
imately 200 ng) were loaded in a nanoEASY trap (Waters) and
then resolved in a 15 cm nanoelute FIFTEEN C18 analytical
column (Bruker Daltonics) at 300 nL/min with a 15 min
gradient (2−35% ACN). Column was heated to 40 °C using an
oven. Mass spectrometer resolution was 50 000 at m/z = 1222,
and ions between 100 and 1700 m/z and charge state 2/3
(selected with the polygon) with an intensity higher than 2500
were specifically selected for fragmentation. Masses below 700
m/z were isolated with a window of 2 Th, and those above 800
m/z with a window of 3 Th, whereas the isolation widths for
masses between 700 and 800m/z were extrapolated from values
between those 2−3 Th. Mass spectrometer operated in PASEF
mode, performing 10 PASEF MS/MS scans for each survey
scan. CID was used for the fragmentation of peptides with a
target precursor intensity set at 2500. Collision energy (CE) for
peptides with mobility below 0.8 V·s/cm2 was 31.92 eV, whereas
for those withmobility above 1.56 V·s/cm2 the CEwas 51.24 eV.
CE for peptides with mobility in between those values is
extrapolated. However, TIMS stepping was used to analyze the
TMT-labeled peptides, meaning that each precursor was
fragmented twice with specific parameters: once for reporter
ion analysis (Collision Rf 700 Vpp, collision energy 140%,
transfer time 40 μs, prepulse storage time 8 μs) and once for
peptide backbone analysis (Collision Rf 1500 Vpp, collision
energy 100%, transfer time 60 μs, prepulse storage time 12 μs).
Dynamic exclusion was applied for 0.4 min with a mass width of
0.015 m/z and a mobility window of 0.015 V·s/cm2, although it
was reconsidered when current intensity/previous intensity is
greater than 4. Protein identification and quantification was
carried out using PEAKS software v.10.5 (Bioinformatics
solutions). Searches were carried out against Human Uniprot
database (version 2020−02−22 April 2020; 20 366 entries)
with precursor and fragment tolerances of 20 ppm and 0.05 Da.
Purity correction was performed following the instructions of
the manufacturer. Peptide-spectra matches were filtered at FDR
< 1%, leading to a 2% FDR at peptide level, using a decoy-fusion
approach. In this approach target and decoy entries of the same
protein are concatenated and further separated after the search
by checking whether they come from the first or the second half
of each concatenated sequence. Thus, the FDR is calculated as
the ratio between the number of decoy hits and the number of
target hits above a given score threshold, where decoy hits are
only kept if they only match decoy protein groups or the decoy
protein score is higher than that of its counterpart target
protein.31 Target proteins were cut off using a −10 log(p)
threshold of 27.5 in order to keep protein-level FDR at 1%. The
Perseus software (1.6.10.50) was used for statistical analysis and
data visualization. Protein quantification was considered valid
with at least two unique peptides for each protein and statistical
significance was calculated by a two-way Student t test (p <
0.05). A fold-change (FC) of 20% was considered to select
differential expressed proteins.
SWATH-MS Proteomics Applied to OB Derived from
PITHD1−/− Mice: MS/MS Library Generation
Wild-type and PITHD1−/−OB specimens were homogenized in
lysis buffer containing 7 M urea, 2 M thiourea, and 50 mMDTT
(6-weeks and 12-weeks-old, n = 3 per group). The homogenates
were spun down at 100 000g for 1 h at 15 °C. Protein
concentration was measured using Bradford assay kit (Biorad).
As an input for generating the SWATH-MS assay library, a pool
of 12 samples (2.5 μg/sample) derived from 6-weeks-old mice
(n = 3/group) and 12-weeks-old mice (n = 3/group) was used.
Protein extracts (30 μg) were diluted in Laemmli sample buffer
and loaded into a 0.75 mm thick polyacrylamide gel with a 4%
stacking gel casted over a 12.5% resolving gel. Total gel was
stained with Coomassie Brilliant Blue and 12 equals slides from
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the pooled sample were excised from the gel and transferred into
1.5 mL Eppendorf tubes. Protein enzymatic cleavage was carried
out with trypsin (Promega; 1:20, w/w) at 37 °C for 16 h as
previously described.32 Peptide mixture was dried in a speed
vacuum for 20 min. Purification and concentration of peptides
were performed using C18 Zip Tip Solid Phase Extraction
(Millipore). Peptides recovered from in-gel digestion processing
were reconstituted into a final concentration of 0.5 μg/μL of 2%
ACN, 0.5% FA, 97.5%Milli-Q-water prior tomass spectrometric
analysis. MS/MS data sets for spectral library generation were
acquired on a Triple TOF 5600+ mass spectrometer (Sciex,
Canada) interfaced to an Eksigent nanoLC ultra 2D pump
system (SCIEX, Canada) fitted with a 75 μm ID column
(Thermo Scientific 0.075× 250 mm, particle size 3 μm and pore
size 100 Å). Prior to separation, the peptides were concentrated
on a C18 precolumn (Thermo Scientific 0.1 × 50 mm, particle
size 5 μm and pore size 100 Å). Mobile phases were 100% water
0.1% formic acid (FA) (buffer A) and 100% Acetonitrile 0.1%
FA (buffer B). Column gradient was developed in a gradient
from 2% B to 40% B in 120 min. Column was equilibrated in
95% B for 10 min and 2% B for 10 min. During all processes, the
precolumn was in line with column and flow was maintained all
along the gradient at 300 nL/min. Output of the separation
column was directly coupled to nanoelectrospray source. MS1
spectra was collected in the range of 350−1250 m/z for 250 ms.
The 35 most intense precursors with charge states of 2 to 5 that
exceeded 150 counts per second were selected for fragmenta-
tion, rolling collision energy was used for fragmentation, and
MS2 spectra were collected in the range of 230−1500 m/z for
100 ms. The precursor ions were dynamically excluded from
reselection for 15 s. MS/MS data acquisition was performed
using AnalystTF 1.7 (Sciex) and spectra files were processed
through ProteinPilot v5.0 search engine (Sciex) using Paragon
Algorithm (v.4.0.0.0)33 for database search. To avoid using the
same spectral evidence in more than one protein, the identified
proteins were grouped based on MS/MS spectra by the
Progroup algorithm, regardless of the peptide sequence
assigned. The protein within each group that could explain
more spectral data with confidence was depicted as the primary
protein of the group. False discovery rate was performed using a
nonlinear fitting method34 and displayed results were those
reporting a 1% Global false discovery rate or better.
SWATH-MSProteomics of OBDerived fromPITHD1−/−Mice:
Quantitative Analysis
Protein extracts (20 μg) from each sample were reduced by
addition of DTT to a final concentration of 10 mM and
incubation at 25 °C for 1 h. Subsequent alkylation by 30 mM
iodoacetamide was performed for 1h in the dark. An additional
reduction step was performed by 30 mM DTT, allowing the
reaction to stand at 25 °C for 1 h. The mixture was diluted to 0.6
M urea using Milli-Q-water, and after trypsin addition
(Promega) (enzyme:protein, 1:50 w/w), the sample was
incubated at 37 °C for 16h. Digestion was quenched by
acidification with acetic acid. The digestion mixture was dried in
a SpeedVac. Purification and concentration of peptides was
performed using C18 Zip Tip Solid Phase Extraction
(Millipore). The peptides recovered were reconstituted into a
final concentration of 0.5 μg/μL of 2% ACN, 0.5% FA, 97.5%
Milli-Q-water prior to mass spectrometric analysis. For
SWATH-MS-based experiments, the instrument (Sciex Triple-
TOF 5600+) was configured as described by Gillet et al.35
Briefly, the mass spectrometer was operated in a looped product
ion mode. In this mode, the instrument was specifically tuned to
allow a quadrupole resolution of Da/mass selection. The
stability of themass selection was maintained by the operation of
the Radio Frequency (RF) andDirect Current (DC) voltages on
the isolation quadrupole in an independent manner. Using an
isolation width of 16 Da (15 Da of optimal ion transmission
efficiency and 1 Da for the window overlap), a set of 37
overlapping windows were constructed covering the mass range
450−1000 Da. In this way, 1 μL of each sample was loaded onto
a trap column (Thermo Scientific 0.1 × 50 mm, particle size 5
μm and pore size 100 Å) and desalted with 0.1% TFA at 3 μL/
min during 10 min. The peptides were loaded onto an analytical
column (Thermo Scientific 0.075 × 250 mm, particle size 3 μm
and pore size 100 Å) equilibrated in 2% acetonitrile 0.1% FA.
Peptide elution was carried out with a linear gradient of 2 to 40%
B in 120 min (mobile phases A:100% water 0.1% formic acid
(FA) and B: 100% Acetonitrile 0.1% FA) at a flow rate of 300
nL/min. Eluted peptides were infused in the mass spectrometer.
The Triple-TOF was operated in swath mode, in which a 0.050 s
TOF MS scan from 350 to 1250 m/z was performed, followed
by 0.080 s product ion scans from 230 to 1800 m/z on the 37
defined windows (3.05 s/cycle). Collision energy was set to
optimum energy for a 2 + ion at the center of each SWATH
block with a 15 eV collision energy spread. The mass
spectrometer was always operated in high sensitivity mode.
The resulting ProteinPilot group file from library generation was
loaded into PeakView (v2.1, Sciex) and peaks from SWATH
runs were extracted with a peptide confidence threshold of 99%
confidence (Unused Score ≥1.3) and a false discovery rate
(FDR) lower than 1%. For this, the MS/MS spectra of the
assigned peptides was extracted by ProteinPilot, and only the
proteins that fulfilled the following criteria were validated: (1)
peptide mass tolerance lower than 10 ppm, (2) 99% of
confidence level in peptide identification, and (3) complete b/
y ions series found in the MS/MS spectrum. Only proteins
quantified with at least two unique peptides were considered.
The quantitative data obtained by PeakView were analyzed
using Perseus software36 for statistical analysis and data
visualization.
Bioinformatics
To obtain in silico biological features of PITHD1, multiple
bioinformatic resources were used: (i) GOA Database for Gene
Ontology annotation,37 (ii) PhosphoSitePlus for PTM profil-
ing,38 (iii) BioGRID database for protein interactions,39 (iv)
ExoCarta/Vesiclepedia for exosomal/vesicle cargo annota-
tion,40,41 and (v) Proteomics DB, PeptideAtlas and Human
Protein Atlas (HPA) for expression/detection analysis in human
fluids, cell lines and tissues.42−44 The PITHD1 coregulated
proteome map and its functionality was generated using
ProteomeHD, STRING and Metascape tools.45−47
Protein Arrays
For the secretome analysis, a dot-blot protein array was used for
cytokine profiling (Abcam). Briefly, membranes with 80
cytokine antibodies were blocked with the manufacturer’s
blocking buffer at room temperature (RT) for 30 min, and
incubated overnight with 1 mL of undiluted cell-cultured media
from control and PITHD1-treated ON cells during 24 h (n = 3/
condition). After washing, a biotinylated anticytokine antibody
mixture was added to the membranes followed by incubation
with HRP-conjugated streptavidin and then exposed to the
manufacturer’s peroxidase substrate. For phosphokinome
analysis, the Proteome Profiler Array (R &D Systems) was
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used according to the manufacturer instructions. Cell lysates
derived from control and PITHD1-treated ON cells during 1 h.
(n = 3) were diluted and incubated overnight with the Human
Phospho-Kinase Array, that contains 43 different capture
antibodies printed in duplicate. The arrays were washed to
remove unbound proteins followed by incubation with a cocktail
of biotinylated detection antibodies. Streptavidin-HRP and
chemiluminescent detection reagents were applied, and a signal
was produced at each capture spot corresponding to the amount
of phosphorylated protein bound. For both protein array
platforms, chemiluminescence signals were quantified with the
ImageQuant ECL system (BioRad) and normalized to the
positive control signals. The Perseus software (version 1.5.6.0)
was used for statistical analysis.36
Western Blotting
Equal amounts of protein (10 μg) were resolved in 4−15% stain
free SDS-PAGE gels (Biorad). Protein extracts derived fromON
cells and OB specimens were electrophoretically transferred
onto nitrocellulose membranes using a Trans-blot Turbo
transfer system (up to 25 V, 7 min) (BioRad). Membranes
were probed with primary antibodies at 1:1000 dilution in 5%
nonfat milk or BSA according to manufacturer instructions.
After incubation with the appropriate horseradish peroxidase-
conjugated secondary antibody (1:5000), the immunoreactivity
was visualized by enhanced chemiluminescence (PerkinElmer)
Figure 1. Representation of the dark proteome across olfactory structures, cell types and interactomes for neuropathological substrates. (A)
Intersection of proteins derived from proteomic expression profiling of human OB and cleft mucus respect to the dark proteome considered by
NeXtProt (2020−17−01 release). (B) Comparison of the actual dark proteomewithmurine cell type-enrichedmarkers for four cell types derived from
mouse (neurons, oligodendrocytes, astrocytes, and microglia) previously obtained by proteomics.50 (C) Cluster-enriched genes in specific murine
mouse OB cell layers (mitral/tufted layer, olfactory sensory neurons, periglomerular layer, granular layer and external plexiform layer)51 that
correspond to components of the dark proteome. (D) Venn diagram representing the overlap between the “synaptic proteome” composed by the three
major databases on synaptic proteins (C2G, SynsysNet, and Synaptome DB) and the dark proteome. (E) Interlocking of dark proteome with the
experimentally validated interactors for neuropathological substrates like APP, MAPT, and SNCA. In all cases, numbers represent the number of
shared proteins in the respective overlapping areas.
Journal of Proteome Research pubs.acs.org/jpr Article
https://dx.doi.org/10.1021/acs.jproteome.0c00452
J. Proteome Res. 2020, 19, 4826−4843
4830
Figure 2. Coregulation analysis of human PITHD1. (A) Coregulation map of human PITHD1. The global coregulation map of ProteomeHD (www.
proteomeHD.net)45 is shown (n = 5013 proteins). Purple dot corresponds to PITHD1, whereas green dots correspond to multiple proteins that tend
to coregulate with PITHD1 across more than 290 biological perturbations. Distances between proteins indicate how similar their expression patterns
are. (B) Top enriched ontology clusters across PITHD1 coregulated proteome by Metascape. (C) Protein interactome network for PITHD1
coregulated proteome. Network analysis was performed submitting the corresponding protein IDs to the STRING (Search Tool for the Retrieval of
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and detected by a Chemidoc MP Imaging System (Bio-Rad).
Equal loading of the gels was assessed using Stain-free imaging
technology. Thus, protein normalization was performed by
measuring total protein directly on the gels used for Western
blotting. After densitometric analyses (Image Lab Software
Version 5.2; Bio-Rad), optical density values were expressed as
arbitrary units and normalized to total protein levels.
■ RESULTS AND DISCUSSION
Enlightenment of the Dark Proteome: Focus on Human
Olfactory Areas
Due to the relevance of the smell sense in neurodegeneration
together with the dispersed information about the olfactory
expression of the dark proteome, we have performed an
exploratory analysis to check the presence of dark proteins in
previous published data sets derived from human OB and cleft
mucus.15,16,48,49 As shown in Figure 1A, 14% of the dark
proteome has been previously detected in these specific
olfactory areas (235 and 37 proteins in human OB and cleft
mucus respectively). Moreover, a small subset of dark proteins
have been considered highly enriched transcripts in specific cell
populations of the murine brain:50 KCTD4 in oligodendrocytes,
GSE1 and PRR12 in neurons, ARMCX4, MROH1, and
ZC2HC1A in microglia and LUZP2, CASKIN2 in astrocytes
(Figure 1B). Cluster-enriched genes in specific OB cell layers
have been recently detected.51 Our analysis has revealed that
part of the dark proteome corresponds to highly expressed genes
in mitral/tufted cell layer (FAM234B, PRNP, FAM171B,UBN2,
C5MD2, LHFPL3, FAM184A, TTC14, FAM193B), olfactory
sensory neurons (WDR89), periglomerular cell layer (SYN-
DIG1L, PCP4L1, FAM49A), granular cell layer (TMEM191C,
UBL3, FAM163B, CTXN3, POLR2M, UBALD2, RPRML,
TTC9B, FAM81A, TMEM243, RSRP1,MRFAP1), and external
plexiform layer (TMEM130) (Figure 1C). On the other hand,
combining the information stored in three repositories
containing the largest number of synapse specific proteins
(G2Cdb, Synaptome DB, and SynsysNet),52−54 we have
observed that 2% of the dark proteome (38 proteins) is part
of synaptic terminals (Figure 1D). Recent studies point out that
the proteome composition of neuropathological aggregates may
differentiate specific pathological entities from the same disease
spectrum.55 We wanted to know whether dark proteins have
been experimentally characterized as interactors of neuro-
pathological substrates. On the basis of the curated interactomic
information present in the BioGrid repository,39 we interlocked
the experimentally validated interactomes for amyloid precursor
protein (APP; 2138 interactors), Tau protein (MAPT; 166
interactors), and alpha-synuclein (SNCA; 485 interactors) with
the dark proteome. As shown in Figure 1E, 5% of the dark
proteome (102 proteins) has been demonstrated as physical
interactor of APP. These compiled data indicate that multiple
dark proteins are expressed in olfactory areas, tend to be
localized at synaptic terminals, and may be involved in
amyloidopathies such as AD, opening doors to new research
projects within the B/D-HBPP initiative.
Functional Bioinformatic Screening for PITHD1
Our group partially characterized the molecular alterations that
accompany the OB neuropathological deposits in tardopathies,
tauopathies, and synucleinopathies.15,16,28,56−63 Our olfactory
proteotyping strategy revealed commonalities and differences
across human AD and PD,15,16,63 suggesting that the shared OB
proteome might be part of a common pathological disarrange-
ment during the olfactory neurodegeneration in both
phenotypes. Specifically, one of the protein components of
this share OB proteome was the dark protein PITHD1,
significantly altered in AD and PD in a neuropathological
state-dependent manner.15,16 The PITHD1 gene is a highly
conserved protein-coding gene located on chromosome 1
(1p36.11) (position 23 778 418 to 23 788 232), that presents
325 orthologs according to NCBI database (Gene ID: 57095;
NX_Q9GZP4, uPE1). Using a plethora of bioinformatic tools,
we have observed that (i) PITHD1 tends to be localized in the
nucleus, (ii) it is targeted by 8 phosphorylations, 5
ubiquitinations, 3 O-GalNAc sites, and 1 methylation site, (iii)
its current protein interactome is mainly involved in tran-
scription, signal transduction and chromatin organization
(Supplementary Figure S1), (iv) PITHD1 is present in
exosome/vesicles and in multiple human fluids like urine,
milk, plasma, and cerebrospinal fluid (CSF), and (v) PITHD1
presents a low specificity across human cell lines and tissues,
being ubiquitously expressed in the brain. On the basis of
isolated findings generated by different unbiased high-
throughput molecular approaches, PITHD1 mRNA/protein
levels has been succinctly related to viral infections,64,65
oncologic treatments,66 and neurological syndromes such as
neurocognitive decline, multiple sclerosis, and bipolar disor-
der.67−69
Taking into account that protein expression profiling is
superior to mRNA expression profiling for prediction of gene
function,70,71 we applied a protein coexpression analysis to
identify functional clues for the uncharacterized PITHD1
protein (Supplementary Table S2A). Using the coregulation
map of the human proteome,45 we observed that PITHD1 tends
to coregulate with mitochondrial protein components (Supple-
mentary Table S2B) mainly involved in nucleotide metabolism,
mitochondrial transport and autophagy (Supplementary Table
S2C, Figure 2A,B). The interactome analysis of the PITHD1
coregulated proteome revealed several protein clusters with a
direct role in oxidative phosphorylation and ER to Golgi vesicle-
mediated transport (Figure 2C). Even though most of PITHD1
experimentally demonstrated interactors correspond to nuclear
proteins, these data suggest a potential role of PITHD1 out of
the nucleus. Interestingly, a subset of PITHD1 coregulated
proteins has been linked to neurological disorders such as AD
and PD (Supplementary Table S2B). Moreover, part of OB
deregulated proteome during AD and PD progression
correspond to PITHD1 coregulated proteins15,16 (Supplemen-
tary Figure S2).
Subsequent analyses were performed to search functional
relationships between PITHD1 and alpha-synuclein, tau, and
beta-amyloid, well-known drivers for the pathological protein
aggregates in a plethora of neurodegenerative diseases.72 On the
Figure 2. continued
Interacting Genes) software (v.10.5) (http://stringdb.org/). To minimize false positives as well as false negatives, only interactions tagged as “highest
confidence” (>0.9) in STRING database were considered. K means clustering was applied (number of clusters: 6).
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basis of the molecular information present in the BioGrid
repository39 only ANKRD39 (uPE1 protein according to
NeXtProt 2020−01−17 release) was common between
PITHD1 coregulated proteome and APP interactome, indicat-
ing that, based on the current knowledge, there is no a direct
association between PITHD1 and the substrates of neuro-
pathological aggregates at protein level.
PITHD1 Early Alters the Olfactory Neuroepithelial
Phosphoproteome
A thorough scan and survey of the published high throughput
proteomic studies in olfaction-related areas has revealed that
PITHD1 has not been detected in olfactory sensory cilia, nasal
mucous, and nasal lavage fluid.49,73,74 However, PITHD1 was
identified in human olfactory neuroepithelium (ON),75 a
peripheral tissue with a high neurogenesis capacity76 responsible
for the initial interaction between the aromatic molecules and
the olfactory sensory neurons (OSNs). This biological material
is frequently used as a surrogate of central nervous system
(CNS) function.77−79 Moreover, PITHD1 has been previously
detected in human CSF.80,81 An olfactory CSF circuit exits
through the olfactory system, running along the lateral olfactory
stria, through the olfactory trigone, and down the olfactory tract
(OT) to the olfactory bulb (OB), where CSF wriggles out
through the cribriform plate to the nasal mucosa.82 With the aim
to decipher the role of PITHD1 in the olfactory system, and
mimicking the effects of exogenous PITHD1 within ON,
subsequent experiments were performed to characterize the
effects of human ON cells upon recombinant PITHD1
(rPITHD1) stimulation. First, we confirmed the purity of the
recombinant protein as well as the presence of the full sequence
of rPITHD1 by double Western blotting against the N- and C-
terminal tags and mass spectrometry (Supplementary Figure
S3A,B). Then, we verified that the presence of FBS in the cell
media does not degrade the recombinant protein during 24 h of
treatment (Supplementary Figure S3C). To identify signaling
events induced soon after rPITHD1 stimulation, phosphokinase
arrays were performed 60 min post-treatment. As shown in
Figure 3, a significant induction in the activation state of some
transcription factors like c-Jun, STAT3, as well as eNOS, RSK1/
2/3, p70 S6 kinase, and AKT was observed in human ON cells.
eNOS, STAT3, and c-Jun have been previously related to
odorant adaptation,83 OSN maturation and death.84,85 All these
evidence together with the activation of kinases involved in cell
survival such as RSK, p70 S6, and AKT point out that PITHD1 is
able to interfere with the proliferative and differentiation state of
the ON.
PITHD1 Reduces Proliferation and Triggers a
Pro-inflammatory Phenotype in Olfactory Neuroepithelial
Cells
Subsequent experiments were performed to analyze the effect of
PITHD1 on cell proliferation. As shown in Figure 4A, PITHD1
induces a growth inhibition in ON cells, displaying a reduction
on cell viability 24 h poststimulation. To characterize in detail
the modulation of ON homeostasis by PITHD1 at intracellular
level, a multiplex isobaric tagging approach (TMT) coupled to
TIMS-TOF mass spectrometry was used (Supplementary Table
S3). Specific markers of OSNs like βIII-tubulin (TUBB3),
microtubule-associated protein 1B (MAP1B) and ubiquitin
carboxyl-terminal hydrolase isozyme L1 (UCHL1) were
detected in ON cells by mass spectrometry (Supplementary
Table S3). However, protein expression of neuronal precursor
or olfactory epithelial stem cell markers77 were not observed in
our ON cultured cells. The alteration in the proliferation rate
was accompanied by a slight modulation of the ON intracellular
proteome at 24 h post-treatment (3626 quantified proteins with
at least 2 unique peptides). This modulation was reflected by the
alteration of 51 proteins in rPITHD1-treated cells compared to
untreated ON cells (20 down-regulated and 31 up-regulated
proteins) (Supplementary Table S4) mainly located at
cytoplasmic, nuclear and membrane-bounded organelle level.
From a functional point of view, the differential protein subset
was involved in the establishment of the endothelial barrier,
signaling by interleukins, JAK-STAT pathway, regulation of
neural precursor cell proliferation, axon guidance, and
respiratory electron transport among others (Figure 4B,
Supplementary Table S5). To complement the intracellular
proteostatic imbalance induced by rPITHD1 in ON cells, we
partially analyzed the secretome by protein arrays. Among the 80
Figure 3. Targeted phosphoproteomic analysis of olfactory neuroepithelial cells upon PITHD1 stimulation. (A) rPITHD1 detection in the cell media
of ON cells after 60 min of treatment. (B) rPITHD1 induces changes in the phosphorylation levels of specific transcription factors and kinases in ON
cells (60 min treatment). Three independent experiments were performed. Data are presented as mean ± SEM *p < 0.05, **p < 0.01 vs unstimulated
ON cells. Representative images of phosphokinase arrays are shown.
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secreted cell−cell signaling molecules analyzed, 7 were
significantly increased upon PITHD1 treatment at 24 h (Figure
4C). Specifically, PITHD1 stimulation induced the production
and secretion of multitasking cytokines such as IL-6 and IL-8
and chemokines like GRO-alpha, RANTES, ENA-78 (epithelial-
cell-derived neutrophil attractant 78) and MCP-1, indicating
that exogenous PITHD1 triggers a pro-inflammatory phenotype
in ON cells. IL-6 is considered the cytokine most sensitive to
OSN injuries,86,87 having inhibitory effects on neural stem cell
differentiation88 and being associated with ON atrophy and loss
Figure 4. (A) Effect of PITHD1 in the proliferative capacity of ON cells. A significant reduction in cell survival was observed in PITHD1-treated ON
cells (24 h) by crystal violet assay. Data are themean± SEM from four independent experiments (**p < 0.01 vs unstimulatedON cells) (left).Western
blotting against poly-His tag in the cell media at 24 h poststimulation (right). (B) Enriched ontology clusters across PITHD1-modulated proteome at
24 h. This analysis was made using Metascape. (C) rPITHD1 induces changes in the extracellular cytokine profiling of ON cells. Eighty cytokines/
growth factors were monitored in the cell media of nontreated ON cells and rPITHD1-treated ON cells (24 h) using a dot-blot protein array method.
Three independent experiments were performed. Data are presented as mean ± SEM ***p < 0.001 vs nontreated ON cells.
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of OSNs.89 These inflammation-like features together with
hallmarks of aged olfactory mucosa90 such as the alteration in
the proliferation rate and extracellular matrix remodelling (up-
regulation of ICAM1, MMP1, NFKB2, PTX3, ANTXR1),
suggest that PITHD1 may contribute to olfactory impairment
during aging. Although our study has uncovered some intricacies
about the role of PITHD1 in ON cells, there are potential
limitations of our study that warrant discussion. The use of E. coli
expressed- rPITHD1 unlikely maintains its tangled PTMprofile,
so additional studies using different expression systems and
mutants will be needed to fully understand the specific role of
each PTM on the PITHD1 functionality at olfactory level.
Early and Time-Dependent Molecular Derangements in
Synaptic Transmission in the Olfactory Bulb of PITHD1−/−
Mice
To examine the functionality of PITHD1 on the olfactory
molecular homeostasis in vivo, we applied olfactory proteomics
in 6-week and 3-month-old PITHD1−/− mice. To analyze the
potential differences in olfactory molecular expression profiles,
OB specimens for each experimental group (PITHD1−/− and
WT mice) were subjected to SWATH-MS. From 2806
quantified proteins, the expression levels of 46 proteins were
found to be significantly different between 6-week-old WT and
PITHD1−/− mice (31 down- and 15 up-regulated proteins with
respect to WT mice), and 30 differentially expressed proteins
were detected at 3 months of age (17 down- and 13 up-regulated
proteins with respect to WT animals) (Supplementary Table
S6). Functional analysis showed that part of the differential
expressed proteins are involved in synaptic transmission
(NQO1, GRM2, OMP, PLCB4, PLCL1, SYT7, USP8,
NRXN2, ADNP, SLC17A6, BRSK1, TPRG1L), detoxification
(NQO1, GSTM1, GSTZ1, PRXL2B, RHOB, USP8, CMBL,
GATM, CARNS1), as well as in cognitive functions such as
learning or memory (GATM, NRXN2, ADNP, UBA6, BRSK1)
(Figure 5). These data point out that PITHD1 plays a role in
olfactory trans-synaptic signaling in vivo.
Olfactory PITHD1 Expression in Aging and
Neurodegeneration
Bearing inmind that our previous olfactory proteotyping applied
in AD and PD63 did not distinguish between the numerous cell
types coexisting in the OB region, immunohistochemical
analyses were performed to map PITHD1 protein expression
in mouse OB.
As shown in Figure 6, PITHD1 is detected in the glomerular
cell layer, external plexiform layer, mitral cell layer, internal
plexiform layer, and granular cell layer. Interestingly, PITHD1 is
not exclusive to the nuclear part, being highly expressed at
dendritic connections and across the neuropil. This protein
profile across all OB cell layers is in accordance with previousOB
single-cell RNA-seq outputs.51 It is well-known that the greatest
known risk factor for the development of most of neuro-
degenerative diseases is aging. Moreover, age-related decline in
Figure 5. Synaptic transmission changes in the OB by PITHD1 deficiency. (A) Immunoblot analysis of PITHD1 protein in OB isolated fromWT and
PITHD1−/−mice. Equal loading of the gel was assessed by stain-free digitalization. (B) Functional clustering of OB differentially expressed proteins in
PITHD1−/−mice respect toWT animals (6-week and 12-week-old mice; n = 3/group). (C) Volcano plot analysis of OB proteomes isolated fromWT
and PITHD1−/− mice. Deregulated synaptic proteins are highlighted.
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olfactory function is very common in the older population.91 On
the basis of this relation, we have observed that OB PITHD1
expression increases with age in wild-type (WT) mice (Figure
7A). However, OB PITHD1 levels are down-regulated in
Tg2576 AD mice at the age of 18 months (Figure 7A), when
transgenic mice show a robust pathology based on beta-amyloid
plaques and behavior impairment.28 According to OB tran-
scriptomic data obtained in aged Tg2576mice,62 the drop in OB
PITHD1 protein levels is not explained by transcriptional
changes, indicating possible fluctuations in the protein
degradation rate when AD pathology is well-established in
Tg2576 mice. The apparent discrepancy in the regulation of OB
PITHD1 levels between human AD and transgenic mice is not
an unexpected observation, because the AD progression in
amyloidogenic AD models is reminiscent of, but not identical
with sporadic human AD. This may be partially explained by
species- and stage-dependent inflammatory mechanisms,92,93
differences in molecular events associated with β-amyloido-
genesis, and the lack of intraneuronal neurofibrillary tangles.
Taking into account that complementary analysis of func-
tionally interconnected areas may provide clues regarding the
olfactory neurodegenerative process, we also focused our
attention on the human olfactory tract (OT). The OT is
constituted by the axons coming from the mitral and tufted
neurons, that extend from the OB to the olfactory cortex. A
significant degeneration of axons has been detected in the OT
from AD subjects,94 correlating with the development of
dementia.95 On the other hand, atrophy and changes in the
structural integrity of OT have been also observed in PD
subjects with respect to controls.96 Subsequent experiments
were performed to characterize PITHD1 protein expression in
OTs derived from AD and PD subjects. In accordance with
previous data obtained at the level of the OB,16 OT PITHD1
expression was significantly higher in AD with respect to
controls (Figure 7B). Interestingly, no changes were observed in
OTs derived from the PD population (Figure 7B). Although
axonal degeneration in OTs is a common feature between both
phenotypes, our data point out that the role of PITHD1 in
olfactory neurodegeneration is disease-dependent. We wanted
to know whether olfactory PITHD1 is also modulated in
additional neurological syndromes with different sensitivity to
olfactory dysfunction. Together with AD and PD, DLB and
mixed dementia (where AD coexists with vascular pathology)
are in the group of neurological disorders with severe smell
impairment, whereas olfactory dysfunction occurs to a lesser
extent or is absent in ALS and PSP.97 For that, Western blot
analyses were performed in dementia with Lewy bodies (DLB; n
= 18), mixed dementia (Dmix; n = 7), amyotrophic lateral
sclerosis (ALS; n = 12), and progressive supranuclear palsy
(PSP; n = 10) cases and compared to control subjects (n = 8). As
shown in Figure 7C, PITHD1 protein levels in OB and OTwere
unchanged across all neurological syndromes tested, suggesting
that OT PITHD1 is specifically upregulated in human AD.
■ CONCLUSION
The smell sense is a tangled sensory system where electro-
biochemical events trigger the conversion of the molecular
information on odorants into odor sensation. Although
phylogenetically ancient, the olfactory system has received less
attention than other sensorial systems and this partially explains
why many dark proteins expressed at the olfactory level are still
uncharacterized (Supplementary Table S7). In fact, the
functional proteomic characterization of olfactory receptors is
a continual challenge,98 hampering the full elucidation of the
pathways for the transmission of olfactory signaling99 as well as
the function of their ectopic expression.100 Since olfactory
dysfunction is considered an early prodromal event in
neurodegenerative diseases, we have investigated the global
expression of dark proteins in human olfactory structures.
Figure 6. Immunohistochemical localization of PITHD1 in normal
mouse OB. Representative immunohistochemical staining pattern of
PITHD1 across OB cell layers (4−10×) (upper and middle) (GL:
glomerular cell layer; EPL: external plexiform layer; MCL: mitral cell
layer; IPL: internal plexiform layer; GCL: granular cell layer). Detail of
PITHD1 expression in the nucleus and olfactory axons (60×) (lower).
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Different bioinformatic workflows have been used to reveal
functional features of poorly annotated human proteins. Zhang
et al. developed a computational approach that generates protein
structure predictions using I-TASSER, inferring GO functional
clues for the Chromosome 17 uPE1 proteome from functional
templates recognized by COFACTOR.101 Using immunohis-
tochemistry analysis and multiomic expression data sets derived
from the testis, Melaine et al. localized multiple missing proteins
and partially deciphered the functional role of specific dark
proteins.102 On the basis of data-mining approaches across
publicly available resources, complementary strategies have
been postulated to greatly facilitate the experimental designs on
dark proteins.103,104 In this work, we have revealed novel
functional features of PITH domain-containing protein 1
Figure 7. PITHD1 expression at the level of theOB andOT across neurological disorders. (A) Time-dependent evolution of theOB Pithd1 inWT and
Tg2576 mice (right panels). Left graph represents the OB Pithd1 expression during the aging process in WT and Tg2576 mice (2-, 6-, and 18-month-
old; n = 3 per group). In all cases, Pithd1 expression was monitored by Western blotting. Equal loading of the gels was assessed by stain-free
digitalization. Panels show histograms of band densities. Data are presented as mean ± standard error of the mean (SEM). (*P < 0.05). (B) Western
blotting analysis of OT PITHD1 in human AD and PD phenotypes. Equal loading of the gels was assessed by GAPDH levels. Panels show histograms
of band densities. Data are presented as mean± standard error of the mean (SEM). (*P < 0.05). (C)Western blotting analysis of OB (left panels) and
OT PITHD1 (right panel) in human dementia with Lewy bodies (DLB), mixed dementia (Dmix), progressive supranuclear palsy (PSP) and
amyotrophic lateral sclerosis (ALS). Equal loading of the gels was assessed by stain-free digitalization. Panels show histograms of band densities. Data
are presented as mean ± standard error of the mean (SEM). (*P < 0.05). Full-length blots/gels are presented in Supporting Information.
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(PITHD1; C1orf128) using an experimental workflow based on
bioinformatics, proteomics, in vitro and in vivo studies (using
transgenic AD mouse model and PITHD1−/− mouse), human
clinico-neuropathological samples and immunological detec-
tions (Figure 8).
In particular, we report that (i) PITHD1 is localized across all
OB cell layers, being highly expressed at nuclear and neuropil
level; (ii) PITHD1 plays a role in trans-synaptic signaling in
vivo; (iii) OB PITHD1 levels increase with age in mice; (iv) OB
PITHD1 is compromised at late stages in Tg2576 AD mice; (v)
OT PITHD1 is a differential feature between human AD and
PD; (vi) PITHD1 specifically modulates signaling routes in ON
cells and (vii) PITHD1 interferes with the proliferation rate of
ON cells, inducing proteostatic changes and promoting a pro-
inflammatory phenotype. We hope that our work will
significantly aid the further characterization of additional dark
proteins in the olfactory system, contributing to a better
understanding of the molecular imbalances that occur in early
phases of the neurodegenerative process.
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